NCT07168486View on ClinicalTrials.gov

CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 28, 2024

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2028

Conditions
B-Cell LymphomaDiffuse Large B Cell Lymphoma (DLBCL)Primary Mediastinal Large B-cell Lymphoma (PMBCL)Follicular LymphomaTransformed Follicular Lymphoma (tFL)Mantle Cell LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaRichter TransformationMarginal Zone Lymphoma
Interventions
BIOLOGICAL

CD19.20.22 CAR T cells

CAR19.20.22 is a type of immunotherapy known as a chimeric antigen receptor T-cells (CAR T-cells).

DRUG

Fludarabine and Cyclophosphamide

Lymphodepletion with Flu-Cy prior to CAR T cell therapy

Trial Locations (1)

21201

University of Maryland, Baltimore, Baltimore

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER